Medprin Regenerative Medical Technologies Co., Ltd. (SHE:301033)
China flag China · Delayed Price · Currency is CNY
54.15
+0.54 (1.01%)
At close: Sep 4, 2026

SHE:301033 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
393.24361.22272.26227.54195.02153.79
Other Revenue
7.617.616.183.330.24-
400.85368.83278.44230.87195.25153.79
Revenue Growth
27.59%32.46%20.61%18.24%26.96%24.51%
Cost of Revenue
84.9175.6157.6341.5831.2627.29
Gross Profit
315.95293.22220.81189.29163.99126.5
Selling, General & Admin
146.86139.42114.04116.17105.5773
Research & Development
37.8436.9627.0926.7830.6125.88
Other Operating Expenses
0.940.420.622.12.040.66
Operating Expenses
185.59176.75141.84145.09138.2599.49
Operating Income
130.36116.4778.9744.225.7427.01
Interest Expense
-0.02-0.02-0.9-2.21-1.78-0.49
Interest & Investment Income
4.454.525.485.459.786.49
Currency Exchange Gain (Loss)
-0.44-0.440.44-0.011.04-0.47
Other Non Operating Income (Expenses)
-2.43-0.54-0.26-0.2-0.13-0.14
EBT Excluding Unusual Items
131.92119.9983.7247.2434.6532.4
Gain (Loss) on Sale of Investments
0.920.190.150.13-0.810.98
Gain (Loss) on Sale of Assets
0.010.010-0.170.01
Asset Writedown
-3.61-2.7-0.48-0.22-1.29-0.07
Other Unusual Items
8.698.699.770.877.2518.28
Pretax Income
137.92126.1793.1648.0239.9651.6
Income Tax Expense
15.5113.0414.37.144.236.92
Earnings From Continuing Operations
122.41113.1378.8540.8835.7344.68
Minority Interest in Earnings
----0.160.03
Net Income
122.41113.1378.8540.8835.8944.71
Net Income to Common
122.41113.1378.8540.8835.8944.71
Net Income Growth
30.55%43.46%92.90%13.89%-19.73%20.95%
Shares Outstanding (Basic)
666666666657
Shares Outstanding (Diluted)
676766666657
Shares Change
2.03%1.87%-0.33%-0.80%17.43%14.83%
EPS (Basic)
1.851.711.200.620.540.79
EPS (Diluted)
1.821.691.200.620.540.79
EPS Growth
27.95%40.83%93.55%14.82%-31.65%5.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
96.28116.0583.2267.6-87.65-86.2
Free Cash Flow Per Share
1.431.731.271.02-1.32-1.52
Dividend Per Share
0.7000.7000.6000.4000.2000.100
Dividend Growth
16.67%16.67%50.00%100.00%100.00%-
Gross Margin
78.82%79.50%79.30%81.99%83.99%82.25%
Operating Margin
32.52%31.58%28.36%19.15%13.18%17.56%
Profit Margin
30.54%30.67%28.32%17.71%18.38%29.08%
Free Cash Flow Margin
24.02%31.46%29.89%29.28%-44.89%-56.05%
EBITDA
156.49142.74104.6768.1138.9933.18
EBITDA Margin
39.04%38.70%37.59%29.50%19.97%21.57%
D&A For EBITDA
26.1326.2725.723.9113.256.17
EBIT
130.36116.4778.9744.225.7427.01
EBIT Margin
32.52%31.58%28.36%19.15%13.18%17.56%
Effective Tax Rate
11.25%10.34%15.35%14.88%10.58%13.41%
Revenue as Reported
368.83368.83278.44230.87195.25153.79
Advertising Expenses
-16.0219.0732.5643.1223.01